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Abstract
w w w  . x x xThe effect of N- 4- 2-N-methyl-N- 1-methyl-2- 2,6-dimethylphenoxy ethylamino -ethyl -phenyl -methanesulfonamide.hydrochloride
 . GYKI-16638; 0.03 and 0.1 mgrkg, i.v. , a novel antiarrhythmic compound, was assessed and compared to that of D-sotalol 1 and 3
.mgrkg, i.v. on arrhythmias induced by 10 min of coronary artery occlusion and 10 min of reperfusion in anaesthetized rabbits. Also, its
cellular electrophysiological effects were studied in rabbit right ventricular papillary muscle preparations and in rabbit single isolated
ventricular myocytes. In anaesthetized rabbits, intravenous administration of 0.03 and 0.1 mgrkg GYKI-16638 and 1 and 3 mgrkg
D-sotalol significantly increased survival during reperfusion GYKI-16638: 82% and 77%, D-sotalol: 75% and 83% vs. 18% in controls,
.  .P-0.05, respectively . GYKI-16638 0.1 mgrkg significantly increased the number of animals that did not develop arrhythmias during
 .reperfusion 46% vs. 0% in controls, P-0.05 . In isolated rabbit right ventricular papillary muscle, 2 mM GYKI-16638, at 1 Hz
 .stimulation frequency, lengthened the action potential duration at 50% and 90% repolarization APD without influencing the resting50 – 90
 .  .membrane potential and action potential amplitude APA . It decreased the maximal rate of depolarization V in a use-dependentmax
manner. This effect was statistically significant only at stimulation cycle lengths shorter than 700 ms. The offset kinetics of this Vmax
block were relatively rapid, the corresponding time constant for recovery of V was 328.2"65.0 ms. In patch-clamp experiments,max
performed in rabbit ventricular myocytes, 2 mM GYKI-16638 markedly depressed the rapid component of the delayed rectifier outward
and moderately decreased the inward rectifier Kq current without significantly altering the slow component of the delayed rectifier and
transient outward Kq currents. These results suggest that in rabbits, GYKI-16638 has an in vivo antiarrhythmic effect, comparable to that
of D-sotalol, which can be best explained by its combined Class IrB and Class III actions. q 2000 Elsevier Science B.V. All rights
reserved.
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1. Introduction
The analysis of the Cardiac Arrhythmia Suppression
 .Trials CAST-I and CAST-II prompted the reconsidera-
tion of prophylactic antiarrhythmic treatment after myocar-
dial infarction. The results shed light on the controversy
that Class IrC type Naq channel blockers, i.e. flecainide
and encainide, increased mortality in survivors of myocar-
dial infarction despite their ability to reduce the number of
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premature ventricular beats The Cardiac Arrhythmia Sup-
 .pression Trial CAST Investigators, 1989; The Cardiac
.Arrhythmia Suppression Trial II Investigators, 1992 . The
results of these trials and those of the ESVEM and CAS-
CADE trials shifted the attention to cardiac Kq channel
blockers Mason, 1993; The CASCADE Investigators,
.1993 .
As a disappointment, in the SWORD trial D-sotalol, a
so-called ‘pure’ Class III antiarrhythmic drug, which is
known to block cardiac Kq channels selectively, was
shown to increase mortality in subsets of patients with
myocardial infarction and lowered ejection fraction Waldo
.et al., 1996 .
0014-2999r00r$ - see front matter q 2000 Elsevier Science B.V. All rights reserved.
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Fig. 1. Chemical structure of GYKI-16638.
Accordingly, special attention has been paid to antiar-
rhythmic drugs with complex effects on different ion
channels and receptors. These include D,L-sotalol a de-
layed rectifier Kq channel blocker and b-adrenoceptor
.  qantagonist and amiodarone a K channel blocker pos-
sessing Naq and Ca2q channel blocking properties and
.antiadrenergic activity . Amiodarone has been shown to
exert a strong antiarrhythmic effect in a number of studies
and is currently considered to be one of the most effica-
cous antiarrhythmic drugs available in clinical practice.
Long-term treatment with amiodarone, however, leads to
the development of serious extracardiac side effects Hille-
.man et al., 1998 . Therefore, it seems worthwhile to pursue
the development of novel amiodarone-like compounds with
marked antiarrhythmic potency but without unwanted ex-
tracardiac side effects.
w w w  .N- 4- 2-N-methyl-N- 1-methyl-2- 2,6-dimethylphenoxy
x x xethylamino - ethyl - phenyl - methanesulfonamide. hydro -
 . chloride GYKI-16638; Fig. 1 is a novel N- phenoxyal-
.kyl -N-phenylalkylamine that has been developed recently.
Although it is not an amiodarone congener, based on its
chemical structure, the compound is expected to show
amiodarone-like electrophysiological effects, i.e. both Class
IrB and Class III properties.
In the present study, we investigated the effect of
GYKI-16638 and D-sotalol on the incidence of coronary
artery occlusion and reperfusion-induced arrhythmias in
anaesthetized rabbits. We also studied the cellular electro-
physiological effects of GYKI-16638 in rabbit right ven-
tricular papillary muscle and in rabbit single isolated ven-
tricular myocytes.
2. Materials and methods
2.1. Animals
Male rabbits weighing 2–3 kg were used for the experi-
ments. The animals were allowed to have tap water and
 .laboratory rabbit chow Altromin, Godollo, Hungary ad¨ ¨ ˝
libitum until the experiment. The animal handling protocol
was reviewed and approved by the Ethics Committee for
the Protection of Animals in Research of the Faculty of
Medicine, University of Szeged, Szeged, Hungary.
2.2. Coronary artery ligation and reperfusion
The animals were anaesthetized with 30 mgrkg pento-
barbitone-Na given intravenously in a volume of 1 mlrkg
into the marginal vein of the right ear. Acute coronary
artery occlusion and reperfusion were performed as de-
 .scribed by Coker 1989 . To measure blood pressure, a
catheter filled with isotonic saline containing 500 IUrml
 .heparin the animals were not heparinized was introduced
into the right carotid artery. The catheter was connected to
a pressure transducer Gould-Statham, P23ID, Hugo Sachs
.Electronik, March-Hugstetten, Germany and blood pres-
sure was recorded on an oscillographic recorder Watanabe,
.WTR 331, Hugo Sachs Electronik . For the infusion of
drugs, another catheter was introduced into the marginal
vein of the left ear.
After tracheal cannulation, thoracotomy was performed
in the fourth intercostal space and artificial ventilation was
started with room air Harvard rodent ventilator, model
.683, Harvard Apparatus, South Natick, MA, USA , with
respiratory volume and rate subsequently adjusted to keep
blood gases and pH within the normal range 7 mlrkgr
.stroke, 40 strokesrmin, respectively . Following pericar-
diotomy, a loose loop of 4–0 atraumatic silk Ethicon,
.Edinburgh, UK was placed around the first branch of the
left circumflex coronary artery just under its origin. Both
ends of the ligature were led out of the thoracic cavity
through a flexible tube.
After stabilization of blood pressure and heart rate
 .approximately 10 min , saline or 0.03 or 0.1 mgrkg
GYKI-16638 or 1 or 3 mgrkg D-sotalol was administered
i.v. during a 1-min infusion in a volume of 2 mlrkg, 5 min
prior to coronary artery occlusion.
Coronary artery occlusion and, thus, local myocardial
ischaemia, was produced by tightening the loose loop and
clamping on the silk. After 10 min of coronary artery
occlusion, the ligature was released to permit reperfusion
for 10 min.
 .The electrocardiogram lead I, II, III was registered
using a thermographic recorder ESC 110 4 CH, Multiline,
.Esztergom, Hungary with subcutaneous needle electrodes.
QT interval was defined as the time between the first
deviation from the isoelectric line during the PR interval
until the end of the TU wave. QT interval corrected for
 .heart rate QT was calculated using the following equa-c
 . tion of Carlsson et al. 1993a : QT sQTy0.175= RRc
.y300 .
Arrhythmias were detected and diagnosed in accordance
with the Lambeth conventions as ventricular tachycardia,
ventricular fibrillation and other types of arrhythmias,
including single extrasystoles, bigeminy, salvos and brady-
 .cardia Walker et al., 1988 .
At the end of the experiment, heparin-Na 500 IUrkg,
.i.v. was administered and the animals were killed. The
hearts were cut out from the chest in order to determine
the size of the occluded zone. After the ligation was
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tightened, the hearts were retrogradely perfused via the
aorta with 20 ml saline and 10 ml of 96% ethanol as
 .previously described by Lepran et al. 1983 . The non-de-´
 .naturated area occluded zone was excised and its extent
is expressed as a percentage of the total wet weight of the
ventricles. Four animals with an occluded zone less than
16% or larger than 32% were excluded from the final
evaluation.
2.3. Drug administration protocol
 .D-Sotalol 1 or 3 mgrkg was dissolved in saline, and
 .GYKI-16638 0.03 or 0.1 mgrkg was dissolved in propy-
lene glycolrsaline, 1:1 mixture. Both drugs were applied 5
min prior to coronary artery ligation in a volume of 2
mlrkg. Each dose was prepared on the day of the experi-
ment. Control animals received propylene glycolrsaline,
1:1 mixture in a volume of 2 mlrkg.
2.4. Measurement of action potential parameters in rabbit
right ˝entricular papillary muscle
Following cervical dislocation, the heart of each animal
was rapidly removed through a right lateral thoracotomy.
The hearts were immediately rinsed in oxygenated Tyrode’s
 .solution containing in mM : NaCl, 115; KCl, 4; CaCl ,2
1.2; MgCl , 1; NaHCO , 21.4; and glucose, 11. The pH of2 3
this solution was 7.35–7.45 when gassed with 95% O and2
5% CO at 378C. The papillary muscles from the right2
ventricle were individually mounted in a tissue chamber
 .volumef50 ml . Each preparation was initially stimu-
 w xlated HSE Hugo Sachs Electronik stimulator type 215rII,
.March-Hugstetten, Germany at a basic cycle length of 500
 .ms frequencys2 Hz , using 2-ms long rectangular con-
stant voltage pulses isolated from ground and delivered
across bipolar platinum electrodes in contact with the
preparation. We applied the following types of stimulation
in the course of the experiments: stimulation with a con-
 .stant cycle length of 500 ms 2 Hz ; stimulation with
different constant cycle lengths ranging from 300 to 5000
ms taking the measurement after the 25th beat.
To determine the recovery of V , extra test actionmax
 .potentials were elicited using single test pulses S in a2
preparation driven at a basic cycle length of 500 ms. The
S –S coupling interval was increased progressively from1 2
the end of the effective refractory period up to 10 s. The
time constant for recovery of V was fitted to a singlemax
exponential function, starting at the 40 ms diastolic inter-
val and ending at 5 s.
Before the control measurement, at least 1 h was al-
lowed for each preparation to equilibrate while being
continuously superfused with Tyrode’s solution. The tem-
perature of the superfusate was kept constant at 378C.
Transmembrane potentials were recorded using a conven-
tional microelectrode technique. Microelectrodes filled with
3 M KCl and having tip resistances of 5–20 mV were
connected to the input of a high impedance electrometer
 .HSE microelectrode amplifier type 309 , which was refer-
enced to the ground. The first derivative of transmembrane
 .potentials V was electronically derived by an HSEmax
 .differentiator type 309 . The voltage outputs from all
amplifiers were displayed on a dual-beam memory oscillo-
scope Tektronix 2230 100 MHz digital storage oscillo-
.scope, Beaverton, OR .
 .The maximum diastolic potential MDP , action poten-
 .tial amplitude APA , and action potential duration mea-
 .sured at 50% and 90% repolarization APD were50 – 90
obtained using software developed in our department
 .HSE-APES . GYKI-16638 was dissolved in dimethyl sul-
 .foxide DMSO as a 1-mM stock solution. After the
control measurements, GYKI-16638 was added to the
tissue bath to obtain a final concentration of 2 mM and the
measurements were repeated after a 30-min incubation
time.
To select the single in vitro concentration, we were
guided by pharmacokinetic studies with GYKI-16638. In
these measurements, the obtained plasma concentration
after GYKI-16638 administration correlated well with the
concentration used in our in vitro studies with GYKI-
16638.
2.5. Whole-cell configuration of the patch-clamp technique
Single ventricular myocytes were obtained by enzy-
 .matic dissociation from New Zealand rabbits 1–2 kg by
 .a technique described earlier in detail Varro et al., 1996 .´
One drop of cell suspension was placed in a transparent
recording chamber mounted on the stage of an inverted
 .microscope TMS; Nikon, Tokyo, Japan , and at least 5
min were allowed for individual myocytes to settle and
adhere to the bottom of the chamber before superfusion
was started. Myocytes that were used were rod-shaped
with clear striations. HEPES-buffered Tyrode solution
served as the normal superfusate in all experiments. This
 .solution contained mM : NaCl 144, NaH PO 0.33, KCl2 4
4.0, CaCl 1.8, MgCl 0.53, glucose 5.5, and HEPES 5.02 2
at pH 7.4.
Patch-clamp micropipettes were made from borosilicate
 .glass capillaries Clark, Reading, UK using a P-97 Flam-
ingrBrown micropipette puller Sutter Instrument Co, No-
.vato, CA, USA . These electrodes had resistances between
1.5 and 2.5 MV when filled with pipette solution contain-
 .ing in mM : K-aspartate 100, KCl 45, K ATP 3, MgCl2 2
1, EGTA 10, and HEPES 5. The pH of this solution was
adjusted to 7.2 by addition of KOH. Nisoldipine 1 mM;
.Bayer, Leverkusen, Germany in the external solution
2q  .eliminated the inward Ca current I . An Axopatch-1DCa
 .amplifier Axon Instruments, Foster City, CA, USA was
used to record the membrane current in the whole-cell
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Table 1
Effect of intravenous administration of D-sotalol and GYKI-16638 on
mean arterial blood pressure, heart rate, QT and QT intervals in anaes-c
thetized rabbits
Group Dose n Before 5 min after
 .mgrkg infusion infusion
Control MBP 19 101"2.8 100"2.6
HR 271"7.2 268"6.6
QT 149"4.0 149"4.4
QT 162"3.4 162"3.8c
D-sotalol 1.0 MBP 13 97"3.2 97"2.7
aHR 272"9.4 252"8.9
aQT 142"4.7 162"5.2
aQT 156"3.9 172"4.0c
3.0 MBP 13 95"3.5 100"3.3
aHR 265"9.7 247"7.9
aQT 150"6.8 167"6.7
aQT 163"5.9 176"5.8c
GYKI-16638 0.03 MBP 14 93"3.4 93"2.8
aHR 273"5.2 259"6.3
QT 150"4.6 159"7.3
QT 164"4.1 171"6.5c
0.1 MBP 17 94"2.7 93"2.5
aHR 270"8.7 253"7.3
a,bQT 140"4.4 166"6.4
aQT 153"3.4 173"4.7c
 .nsNumber of animals, MBPsmean blood pressure mm Hg , HRs
 .  .heart rate 1rmin , QTsQT interval ms , QT sQT interval.c c
aP -0.05, compared to the preinfusion value of the same group.
bP -0.05, compared to the control group.
configuration of the patch-clamp technique. After a high
 .1–10 GV resistance seal was established by gentle suc-
tion, the cell membrane beneath the tip of the electrode
was disrupted by further suction or by application of 1.5 V
electrical pulses applied for 1–5 ms. Series resistance was
typically 4–8 MV prior to compensation 50–80%, de-
.pending on the voltage protocol utilized . Experiments,
where the series resistance was high, or where it increased
substantially during measurement, were terminated and the
data were discarded. Membrane currents were digitized
using a 333-kHz analog-to-digital converter Digidata 1200,
. Axon Instruments under software control pClamp 6.0,
.Axon Instruments . Analyses were performed using Axon
 .pClamp 6.0 software after low-pass filtering at 1 kHz.
All patch-clamp data were collected at 378C.
GYKI-16638 was diluted at the time of use from a
10-mM stock solution containing 100% DMSO. DMSO at
 .the resulting concentrations 0.2% produced no dis-
cernible effect on APD or the membrane currents assessed.
All stock solutions were prepared using HEPES-buffered
Tyrode solution as the solvent.
2.6. Statistical e˝aluation
For the evaluation of data obtained from the cellular
electrophysiology experiments, Student’s t-test for paired
data was used. All data are expressed as means"standard
 .error of the mean S.E.M. .
The incidence of arrhythmias was calculated and com-
pared by using the x 2 method. All other variables are
expressed as means"S.E.M. and, after analysis of vari-
ance, were compared by means of the modified t statistic
 .of Wallenstein et al. 1980 . Differences were considered
significant when P values were less than 0.05.
3. Results
3.1. Effect of GYKI-16638 on haemodynamic ˝ariables in
anaesthetized rabbits
There were no significant differences between the mean
arterial blood pressures of control and D-sotalol- or GYKI-
16638-treated animals. Mean arterial blood pressure fell
significantly in all groups due to coronary artery occlusion
as compared to preocclusion values 74"3.9 vs. 101"2.8
mm Hg, 78"4.5 vs. 97"3.2 mm Hg, 84"2.6 vs.
95"3.5 mm Hg, 69"3.8 vs. 93"3.4 mm Hg and
74"3.9 vs. 94"2.7 mm Hg in controls, 1 and 3 mgrkg
D-sotalol-, 0.03 and 0.1 mgrkg GYKI-16638-treated ani-
.mals, respectively, all P-0.05 .
The infusion of 1 and 3 mgrkg D-sotalol, as well as
0.03 and 0.1 mgrkg GYKI-16638, significantly decreased
the heart rate of rabbits compared to the basal values
Table 2
Effect of D-sotalol and GYKI-16638 on the incidence of arrhythmias during 10 min of coronary artery occlusion in anaesthetized rabbits
 .  .Group Dose mgrkg n Incidence of arrhythmias Nr%
None VF VT Other
 .  .  .  .Control 19 4r19 21% 8r19 42% 2r19 11% 14r19 74%
 .  .  .  .D-Sotalol 1.0 13 5r13 38% 1r13 8% 0r13 0% 8r13 62%
 .  .  .  .3.0 13 7r13 54% 1r13 8% 0r13 0% 6r13 46%
 .  .  .  .GYKI-16638 0.03 14 3r14 21% 3r14 21% 2r14 14% 11r14 79%
 .  .  .  .0.1 17 5r17 29% 4r17 24% 0r17 0% 12r17 71%
nsTotal number of animals; Nsnumber of animals exhibiting the given response; %spercentage of the animals exhibiting the given response.
VFsventricular fibrillation; VTsventricular tachycardia; Othersextrasystoles, salvos, andror bigeminy.
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Table 3
Effect of D-sotalol and GYKI-16638 on the incidence of arrhythmias during 10 min of reperfusion following 10 min of coronary occlusion in anaesthetized
rabbits
 .  .Group Dose mgrkg n Incidence of arrhythmias Nr%
None VF VT Other
 .  .  .  .Control 11 0r11 0% 9r11 82% 7r11 64% 5r11 46%
a .  .  .  .D-Sotalol 1.0 12 4r12 33% 3r12 25% 4r12 33% 8r12 67%
a .  .  .  .3.0 12 4r12 33% 2r12 17% 4r12 33% 9r12 75%
a .  .  .  .GYKI-16638 0.03 11 3r11 27% 2r11 18% 4r11 36% 9r11 82%
a a .  .  .  .0.1 13 6r13 46% 3r13 23% 6r13 46% 8r13 62%
nsTotal number of animals; Nsnumber of animals exhibiting the given response; %spercentage of the animals exhibiting the given response.
VFsventricular fibrillation; VTsventricular tachycardia; Othersextrasystoles, salvos, andror bigeminy.
aP-0.05.
 .Table 1 . Coronary occlusion did not change heart rate
significantly compared to preocclusion values. No signifi-
cant changes occurred in the heart rate of animals during
reperfusion.
3.2. Effect of GYKI-16638 on QT and QT inter˝als inc
anaesthetized rabbits
D-Sotalol infusion, in the dose of 1 and 3 mgrkg,
 .significantly lengthened QT and QT intervals Table 1 .c
GYKI-16638, in the dose of 0.03 mgrkg, had no effect on
QT and QT intervals, but caused a significant increase ofc
both variables in the dose of 0.1 mgrkg. No significant
changes occurred in the QT or QT intervals during reper-c
fusion.
3.3. Arrhythmias during 10 min of myocardial ischaemia
In all groups, arrhythmias did not develop either during
the 1-min infusion of drugs or vehicle, or between the
infusion of drugs and coronary occlusion.
Fig. 2. Effect of 2 mM GYKI-16638 on the action potential in rabbit right
 .ventricular papillary muscle stimulation frequency: 2 Hz .
The incidence of arrhythmias in the control, D-sotalol-
and GYKI-16638-treated groups during 10 min of coro-
nary artery occlusion is shown in Table 2. The incidence
of ventricular fibrillation was not statistically different in
the D-sotalol- or GYKI-16638-treated animals compared to
the control group.
There were no significant differences in the treated and
control groups with respect to the incidence of other types
of arrhythmias during 10 min of coronary artery ligation.
3.4. Reperfusion-induced arrhythmias
Arrhythmias induced by reperfusion appeared within
10–30 s following the release of the coronary artery
ligature.
 .D-Sotalol 1 and 3 mgrkg and 0.03 mgrkg GYKI-
16638 pretreatment significantly reduced the incidence of
 .reperfusion-induced ventricular fibrillation Table 3 . All
drug pretreatments significantly increased the number of
animals surviving reperfusion 75% and 83% with 1 and 3
mgrkg D-sotalol, 82% and 77% with 0.03 and 0.1 mgrkg
.GYKI-16638 vs. 18% in controls, P-0.05, respectively .
The number of animals that did not develop any ar-
rhythmia during reperfusion was significantly higher in the
Table 4
The effect of 2 mM GYKI-16638 on the action potential parameters in
rabbit right ventricular papillary muscle
ns6 Control 2 mM GYKI-16638
 .RP mV y89"1.5 y91"0.8
 .APA mV 111.7"2.1 112"2.8
a .APD ms 158.3"12.4 194.5"12.750
a .APD ms 205.8"15.9 254.8"14.990
a .V Vrs 208.3"32.8 169.2"20.8max
RPs resting potential; APA saction potential amplitude; APD s50%50
repolarization time; APD s90% repolarization time; V smaximum90 max
upstroke velocity; stimulation frequency: 2 Hz.
aP -0.05.
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 .Fig. 3. Frequency-dependent effect of 2 mM GYKI-16638 on maximum upstroke velocity V and APD in rabbit right ventricular papillary muscle.max
 . q  .  .Fig. 4. Effect of 2 mM GYKI-16638 A on the rapid component of the delayed rectifier outward K current I , B on the transient outward currentKr
 .  . q  .  .  .I , C on the slow component of the delayed rectifier K current I , and D on the inward rectifier potassium current I . Pulse protocols areto Ks k1
shown as insets.
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 .0.1 mgrkg GYKI-16638-treated group Table 3 . There
were no differences in the incidence of other types of
arrhythmias between the animals receiving pretreatment
 .and control rabbits during reperfusion Table 3 .
3.5. Effect of GYKI-16638 on the action potentials in
rabbit papillary muscle
The effect of 2 mM GYKI-16638 on the action poten-
tials at 2 Hz stimulation frequency in rabbit right ventricu-
lar papillary muscle is shown in Fig. 2 and Table 4. At 2
Hz stimulation frequency, 2 mM GYKI-16638 did not
significantly influence the resting membrane potential and
the APA, but it lengthened repolarization, measured as
APD and APD . The maximal rate of depolarization50 90
 .V was also significantly reduced. The observed de-max
crease of V in the presence of 2 mM GYKI-16638 wasmax
use-dependent and became significant only at stimulation
 .cycle lengths shorter than 700 ms Fig. 3 . This was
consistent with a delayed recovery of V measured in themax
presence of the drug t-30 ms in controls, and 328.2"
 . .65.0 ms, ns4 with 2 mM GYKI-16638 . The APD
prolongation induced by 2 mM GYKI-16638 was reverse
use-dependent: the slower the stimulation frequency, the
 .more pronounced the APD prolongation Fig. 3 .
3.6. Effect of GYKI-16638 on ˝arious transmembrane K q
currents in isolated rabbit ˝entricular myocytes
The effect of GYKI-16638 on various Kq currents was
studied in isolated single rabbit ventricular myocytes Fig.
.4 . The rapid component of the delayed rectifier outward
q  .K current I was elicited from y40 mV holdingKr
potential to various 1-s long test pulses ranging from y20
to q50 mV and then returning back to y40 mV. The
amplitude of the deactivating tail current at this potential
was measured as the difference between the peak tail
current and the holding current level and was attributed to
 .I at q50 mV, it was 86.9"16.6 pA, ns4 . BecauseKr
of the very slow deactivation of I , the pulsing frequencyKr
in these experiments was 0.01 Hz. As Fig. 4A shows, 2
mM GYKI-16638 completely inhibited the I tail current.Kr
Similar results were obtained in three other cells.
Fig. 4B and C shows that 2 mM GYKI-16638 did not
change or only minimally affected the transient outward
 . qI and the slow component of the delayed rectifier Kto
currents. Similar results were found in three other cells.
The effect of 2 mM GYKI-16638 on the inward recti-
q  .fier K current I was studied at a holding potential ofk1
y80 mV and was elicited by 300-ms long voltage pulses
to various potentials ranging from y140 to 0 mV. I wask1
determined as the steady-state current at the end of the
voltage pulses. As a result of a representative experiment,
Fig. 4D shows that 2 mM GYKI-16638 moderately de-
creased the amplitude of the steady state current–voltage
relationship attributed to inhibition of I . This effect wask1
reversible upon 5 min of washout. The average value of
 .the I current ns7 at y100 mV before drug superfu-k1
sion was y2648"399 pA, which was significantly re-
duced to y2152"401 pA after 5 min of superfusion with
2 mM GYKI-16638.
4. Discussion
The recently developed GYKI-16638 is a member of a
 .new series of N- phenoxyalkyl -N-phenylalkylamine com-
pounds. Its structure combines Class IrB and Class III
structural elements, i.e. those of D-sotalol and mexiletine.
In the present study, the antiarrhythmic effect of GYKI-
16638 in anaesthetized rabbits and its electrophysiological
effects in rabbit right ventricular papillary muscle prepara-
tions were investigated. We compared the antiarrhythmic
effect of GYKI-16638 to that of D-sotalol, a well-known
pure Class III antiarrhythmic agent.
GYKI-16638 exerted an antiarrhythmic effect in our
experiments that was comparable to that of D-sotalol. Both
compounds significantly decreased the number of animals
that died due to lethal ventricular arrhythmias during reper-
fusion after 10 min of regional myocardial ischaemia. The
significant improvement of survival during reperfusion
occurred in spite of the fact that there were animals that
had reversible ventricular fibrillation in the control group
as well. This is a well-known phenomenon in experimental
arrhythmia studies, i.e. relatively small hearts can recover
from ventricular fibrillation, while in human and large
animal hearts, this arrhythmia is irreversible Botting et al.,
.1986 .
The antiarrhythmic activity of GYKI-16638 was already
observed after the administration of the lower dose which
did not influence QT and QT intervals. This may suggestc
that GYKI-16638 has a mechanism of action that is based
not solely on the prolongation of repolarization. Indeed, it
was found that GYKI-16638 not only caused a significant
increase in APD and, consequently, in the effective refrac-
tory period, but that it also significantly reduced the maxi-
 .mum upstroke velocity V in rabbit right ventricularmax
q  .papillary muscles, reflecting its fast Na channel INa
blocking ability. However, it was found that, in a higher
dose, it significantly prolonged the QT and QT intervalsc
in anaesthetized rabbits, as was expected from its in vitro
effect on the APD. The Naq channel blocking effect was
significant only at cycle lengths shorter than 700 ms. This
was consistent with the measured time constant for recov-
ery of V , which resembled that of Class IrB type drugsmax
 .  .Campbell, 1983 and amiodarone Varro et al., 1985 .´
Such an effect may have therapeutic importance in the
inhibition of arrhythmias due to early afterdepolarizations
 .Papp et al., 1996 .
D-Sotalol has been shown to exert an antiarrhythmic
effect in a number of animal Lynch et al., 1985; Usui et
( )I. Baczko et al.rEuropean Journal of Pharmacology 404 2000 181–190´188
.al., 1993; Hashimoto et al., 1995 and human studies
 .Hohnloser et al., 1995; Koch et al., 1995 with a proposed
mechanism of action of terminating re-entry Fei and
.Frame, 1996 . However, it was shown in the SWORD trial
that D-sotalol increased mortality in patients with myocar-
 .dial infarction Waldo et al., 1996 . The results shifted
attention towards antiarrhythmic compounds with a com-
bined mechanism of action. As an example, amiodarone,
an antiarrhythmic agent with a complex mode of action,
has attracted a great deal of interest recently. It has been
shown to decrease ventricular fibrillation vulnerability in
rabbit hearts following long-term pretreatment Behrens et
.al., 1997 , to be protective against ischaemia- and reperfu-
sion-induced arrhythmias Varro and Rabloczky, 1986;´
.Coker and Chess-Williams, 1991; Li and Northover, 1992 ,
and to be effective in the treatment of life-threatening
 .ventricular arrhythmias in humans Singh, 1999 . Also,
some multicenter clinical trials have shown that amio-
darone may reduce the incidence of arrhythmia-related
 .sudden death Julian et al., 1997; Cairns et al., 1997 .
Several electrophysiological studies showed that amio-
darone possessed both Class IrB and Class III antiarrhyth-
mic properties Singh and Vaughan Williams, 1970; Varro´
.et al., 1985; Honjo et al., 1991; Maruyama et al., 1995 , as
2q  .well as Ca channel blocking Nattel et al., 1987 and
 .sympatholytic effects Polster and Broekhuysen, 1976 .
While effectively diminishing the development of re-entry
arrhythmias, selective I blockers can increase the inci-Kr
dence of arrhythmias, by increasing the interventricular
dispersion of repolarization and initiating early afterdepo-
larizations, leading to torsade de pointes tachycardia
 .Verduyn et al., 1997; Hohnloser, 1997 . It was demon-
strated that almokalant, a selective I blocker, signifi-Kr
cantly reduced the incidence of coronary artery occlusionr
reperfusion-induced arrhythmias but also showed marked
proarrhythmic activity Carlsson et al., 1993a; Farkas et
.al., 1998 . D-Sotalol has also been shown to induce tor-
sades de pointes in animals Buchanan et al., 1993; Vos et
.  .al., 1995 and humans Gottlieb et al., 1997 .
Amiodarone was found to have a remarkably low poten-
tial for inducing torsades de pointes tachyarrhythmias de-
spite its ability to prolong the QT interval Hohnloser etc
.al., 1994 . The decrease in the transmural dispersion of
ventricular repolarization and the consequent inhibition of
the development of early afterdepolarization can possibly
 .explain this effect of amiodarone Sicouri et al., 1997 .
Class IrB antiarrhythmics may reduce the occurrence of
this arrhythmia. Mexiletine Shimizu and Antzelevitch,
.  .1997 and lidocaine in both animal Carlsson et al., 1993b
 .and human studies Assimes and Malcolm, 1998 were
shown to suppress torsades de pointes induced by D-sota-
lol. Antiarrhythmic drugs with a Class IrB action have
also been shown to be effective against coronary artery
occlusionrreperfusion-induced arrhythmias Bonaduce et
al., 1986; Uematsu et al., 1986; He et al., 1992; Komori et
.al., 1995 . Also, the combination of mexiletine and sotalol
prevented ventricular tachycardia induced by programmed
stimulation in dogs with chronic infarction Chezalviel et
.  .al., 1993 , and Luderitz et al. 1991 concluded in their
review that in humans, the combination of mexiletine and
sotalol suppressed both premature ventricular beats and
complex ventricular arrhythmias more effectively than so-
talol alone. These results suggest that an antiarrhythmic
compound with combined Class III and Class IrB effects
could reduce the incidence of re-entry arrhythmias without
a high risk of inducing torsades de pointes arrhythmias.
The exact ionic mechanism of the electrophysiologic
and antiarrhythmic effects of GYKI-16638 is not fully
understood. As mentioned above, the use-dependent de-
pression of V strongly argues for inhibition of the fastmax
inward Naq current. The APD lengthening effect of the
compound can be best explained by the marked depression
of I and, to a lesser extent, by the decrease of the I .Kr k1
Therefore, based on the cellular electrophysiological mea-
surements, GYKI-16638 can be regarded as an antiarrhyth-
mic compound which — like amiodarone Varro et al.,´
.1996; Kodama et al., 1997 — interferes with multiple
transmembrane ion channels.
When administered chronically, amiodarone exhibits
serious extracardiac side effects that limit its use Hilleman
. et al., 1998 . GYKI-16638 shares some Class IrBq
.Class III , but not all of the electrophysiological properties
of amiodarone and its chemical structure is also different.
Based on its different chemical structure, it can be reason-
ably expected that this compound, unlike amiodarone, will
be relatively free of extracardiac side effects. Due to its
Class IrB action, it is also expected that the compound
will lack the significant inhibitory effect on conduction at
a normal heart rate. The compound also showed reverse
frequency-dependent prolongation of APD in rabbit papil-
 .lary muscle Fig. 3 , an effect which resembles that of
D-sotalol or any specific I blocker. Therefore, furtherKr
studies are needed to elucidate the possible side effects of
GYKI-16638, including its capability to induce torsades de
pointes or conduction disturbance-related arrhythmias.
The haemodynamic side effects of antiarrhythmic agents
are of particular importance. GYKI-16638 did not change
the mean arterial blood pressure, but decreased the heart
rate of anaesthetized rabbits. We also found that the ad-
ministration of D-sotalol significantly decreased heart rate
in rabbits. A similar heart rate decreasing effect of D-sota-
 .lol has been shown by Schwartz et al. 1987 , although this
compound lacks the antiadrenergic properties of D,L-sota-
lol. A moderate decrease in heart rate may be beneficial,
especially in the setting of myocardial ischaemia and
 .reperfusion-induced arrhythmias Bernier et al., 1989 .
In conclusion, we demonstrated that GYKI-16638, a
novel antiarrhythmic drug candidate, protected against
coronary artery occlusion and reperfusion-induced arrhyth-
mias in anaesthetized rabbits. This protection was already
noticed at a lower dose, which did not lengthen the QTc
interval significantly. Based on the results of our cellular
( )I. Baczko et al.rEuropean Journal of Pharmacology 404 2000 181–190´ 189
electrophysiological investigations in rabbit right ventricu-
lar papillary muscle, it can be assumed that GYKI-16638
exerts its antiarrhythmic effect through combined Class
IrB and Class III actions.
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